Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampersand Capital acquires Purna Pharmaceuticals
The move is part of Ampersand’s strategy to establish a trans-Atlantic pharmaceutical development partnership through the Purna and MedPharm alliance. This partnership has the potential to become a
The move is part of Ampersand’s strategy to establish a trans-Atlantic pharmaceutical development partnership through the Purna and MedPharm alliance. This partnership has the potential to become a
This approval provides a new option for long-term disease control in patients, with twice-yearly maintenance dosing after two initial loading doses. gMG is a rare, chronic, B-cell-mediated autoimmune
The agreement focuses on expanding Lymphir’s international access via country-specific managed access programmes, where permitted by local regulations. Under the terms, Uniphar will act as the exclusive distributor
The therapies are approved as second or third line treatment for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express programmed death-ligand 1 (PD-L1)
Under the agreement, Biocodex will hold an exclusive worldwide licence to develop and commercialise Batten-1, which has been developed by THX Pharma for juvenile Batten disease (CLN3). Additionally,
The companies plan to jointly develop at least two research and development (R&D) programmes using Insilico Medicine’s AI platform alongside CMS’ expertise in clinical development. Under the agreement,
The FDA accepted the gene therapy’s application under the accelerated approval pathway in May 2025. The CRL indicated that the FDA agreed in principle with the study protocol
The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation. Through this arrangement, Takeda will
The partnership represents the seventh agreement between the two companies and aims to expedite the delivery of new therapies to patients worldwide. Under the agreement, Innovent will utilise
Set to open in 2029, the facility will cover approximately 466,000ft² and accommodate 1,000 employees. The centre will connect with other Novartis global research locations in Basel, Switzerland,